Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 455 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Clinical High-Risk Clear all
Recruiting Phase 2 Interventional

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

NCT04114136
View directory record Official record
Conditions
Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer, Gastric Adenocarcinoma, HNSCC, Esophageal Adenocarcinoma, Microsatellite Instability-High Solid Malignant Tumor
Interventions
Nivolumab or Pembrolizumab (dependent upon approved indication), Metformin, Rosiglitazone
Drug
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 23, 2026, 5:05 AM EDT
Completed No phase listed Observational

7T MRI to Evaluate Cartilage Defects in the Knee

NCT04118023
View directory record Official record
Conditions
Cartilage Injury, Knee Injuries, Arthropathy of Knee, Cartilage Damage, Knee Pain Swelling
Interventions
7 Tesla Magnetic Resonance Imaging Test
Diagnostic Test
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Not applicable Interventional

The Effects of Adding a Home Exercise Program to a Clinical Physical Therapy Program on Cancer-Related Fatigue

NCT00840554
View directory record Official record
Conditions
Fatigue
Interventions
Clinic-based physical therapy program., Home exercise program.
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Phase 2 Interventional

Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma

NCT00006219
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
clarithromycin, prasterone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 4, 2011 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

Medical Treatment of "High-Risk" Neurofibromas

NCT00846430
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
Peg-Interferon alpha-2b, Celecoxib (Celebrex), Temozolomide (temodar), Vincristine Sulfate (Oncovin)
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
2 Years to 30 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients

NCT00689819
View directory record Official record
Conditions
Hypertension, High Blood Pressure, Ventricular Hypertrophy, Diastolic Dysfunction, Systolic Dysfunction
Interventions
Exercise, Weight Loss, Low Sodium Diet, Smoking Cessation, Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)
Behavioral · Drug
Lead sponsor
Wayne State University
Other
Eligibility
35 Years to 75 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Kombucha on Blood Sugar Levels in Humans

NCT04051294
View directory record Official record
Conditions
Glucose, Glucose Metabolism Disorders (Including Diabetes Mellitus), Blood Sugar; High
Interventions
Commercial kombucha tea, Brewed kombucha tea, Control: Tea, Control: Water
Dietary Supplement · Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
30 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 23, 2026, 5:05 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)

NCT04644029
View directory record Official record
Conditions
HIV-I, Human Immunodeficiency Virus Type 1, Prophylaxis
Interventions
Islatravir, Placebo to FTC/TDF, FTC/TDF, Placebo to ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years to 45 Years · Female only
Enrollment
730 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 23, 2026, 5:05 AM EDT
Recruiting Phase 1 Interventional

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

NCT07225439
View directory record Official record
Conditions
Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma
Interventions
Allogeneic NK cells, Rituximab, Tafasitamab, Interleukin-2, Fludarabine/cyclophosphamide
Drug
Lead sponsor
Paolo Caimi, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 5:05 AM EDT
Recruiting Not applicable Interventional

Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.

NCT07168993
View directory record Official record
Conditions
Lung Cancer (Diagnosis)
Interventions
Standard medical treatment
Other
Lead sponsor
bioAffinity Technologies Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
2,063 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Palo Alto, California • Grand Junction, Colorado • Bay Pines, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia

NCT02583893
View directory record Official record
Conditions
Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
Sirolimus, Mitoxantrone, Etoposide, Cytarabine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 23, 2026, 5:05 AM EDT
Withdrawn Phase 1 Interventional

Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy

NCT05796271
View directory record Official record
Conditions
Lymphoma, B-Cell
Interventions
R-Chop and Roflumilast
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

High Dose Risankizumab for Psoriasis

NCT05283135
View directory record Official record
Conditions
Psoriasis
Interventions
risankizumab
Drug
Lead sponsor
Oregon Medical Research Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 23, 2026, 5:05 AM EDT
Active, not recruiting Not applicable Interventional

Quantra Point-of-Care Hemostasis Monitoring

NCT06328647
View directory record Official record
Conditions
Bleeding, Hemostatic Disorder
Interventions
POC Quantra QPlus System, Routine care
Device · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Phase 1 Interventional

Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer

NCT00033345
View directory record Official record
Conditions
Breast Cancer
Interventions
Indole-3-carbinol, Placebo
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Oct 23, 2026, 5:05 AM EDT
Active, not recruiting Phase 2 Interventional

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

NCT03449108
View directory record Official record
Conditions
Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone, Malignancy in Giant Cell Tumor of Bone, Malignant Solid Neoplasm, Ovarian Carcinosarcoma, Platinum-Resistant Ovarian Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Osteosarcoma, Recurrent Ovarian Carcinoma, Refractory Osteosarcoma, Soft Tissue Sarcoma, Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Triple Negative Breast Cancer
Interventions
Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1, Cyclophosphamide, Fludarabine, Ipilimumab, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The GoodNEWS Lifestyle Enhancement Program

NCT00669630
View directory record Official record
Conditions
Cardiovascular Disease, Hypertension, Diabetes, Obesity
Interventions
Lay Health Promoter (LHP) with maintenance
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
392 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors

NCT00302159
View directory record Official record
Conditions
High Grade Gliomas, Brain Tumors
Interventions
adjuvant therapy, Temozolomide, Valproic Acid, Radiation therapy
Procedure · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
3
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Phase 3 Interventional

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

NCT00024427
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Pancreatic Cancer
Interventions
fluorouracil, gemcitabine hydrochloride, triacetyluridine
Drug
Lead sponsor
Wellstat Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
26
States / cities
Birmingham, Alabama • Burbank, California • Duarte, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

NCT02060188
View directory record Official record
Conditions
Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer
Interventions
Ipilimumab, Nivolumab, Cobimetinib, Daratumumab, BMS-986016
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
14
States / cities
Gilbert, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 23, 2026, 5:05 AM EDT
Terminated No phase listed Observational

A Biomarker Screening Protocol for Participants With Solid Tumors

NCT05891197
View directory record Official record
Conditions
Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer
Interventions
Not listed
Lead sponsor
Lyell Immunopharma, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Rocky Mount, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

NCT00416455
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma, Stage I Endometrial Carcinoma, Stage IB Cervical Cancer, Stage II Endometrial Carcinoma, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage IVA Cervical Cancer
Interventions
fludeoxyglucose F 18, positron emission tomography, computed tomography, ferumoxtran-10, magnetic resonance imaging, diagnostic lymphadenectomy, lymph node biopsy
Radiation · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
24
States / cities
Los Angeles, California • Sylmar, California • New Britain, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers

NCT04333225
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Oct 23, 2026, 5:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Retrospective Clinical Trial Comparing Radiologists' Diagnosis Accuracy in Lung Cancer Screening Population With and Without the Help of an AI/ML Tech-based SaMD

NCT06751576
View directory record Official record
Conditions
High Risk Cancer, Lung Cancer
Interventions
Median LCS
Device
Lead sponsor
Median Technologies
Industry
Eligibility
50 Years to 80 Years
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Memphis, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 23, 2026, 5:05 AM EDT